CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has named a new program to its pipeline: ALN-HBV for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback